Sopherion has the US and Canadian rights to this liposomal nanotechnology that targets the tumor vasculature.
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada.Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 19, 2009 | Series C | $55M | 1 | Zoticon BioVentures | — | Detail |
Jan 1, 2008 | Series Unknown | $35M | 1 | Zoticon BioVentures | — | Detail |
Sep 24, 2004 | Series B | $47M | 2 | — | — | Detail |
Mar 10, 2003 | Series A | $26M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Zoticon BioVentures | Yes | Series C |
Commerce Health Ventures | — | Series B |
Seaflower Ventures | — | Series B |
GE Capital Life Science and Technology Finance | — | Series A |